Filtered By:
Condition: Hemorrhagic Stroke
Drug: Warfarin

This page shows you your search results in order of date. This is page number 13.

Order by Relevance | Date

Total 721 results found since Jan 2013.

Comparative Effectiveness and Safety of Direct Oral Anticoagulants in Obese Patients with Atrial Fibrillation
ConclusionsIn this large cohort of obese Veterans Health Administration system patients, the use of DOACs resulted in lower hemorrhagic complications than warfarin while maintaining efficacy on ischemic stroke prevention.
Source: Cardiovascular Drugs and Therapy - January 6, 2021 Category: Cardiology Source Type: research

Comparative effectiveness and safety of non-vitamin k antagonist oral anticoagulants and warfarin in older adults with atrial fibrillation and diabetes.
CONCLUSION: Oral anticoagulation therapy with NOACs was found to be more effective than warfarin therapy among older adults with NVAF and comorbid DM. PMID: 33327796 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - December 18, 2020 Category: Research Tags: Curr Med Res Opin Source Type: research

Anticoagulation Resumption in a Patient With Mechanical Heart Valves, Antithrombin Deficiency, and Hemorrhagic Transformation Following Thrombectomy After Ischemic Stroke
This study is the first report of administering argatroban and titrating to its appropriate dose in the patient with valve thrombosis, antithrombin deficiency, and HT after mechanical thrombectomy for acute ischemic stroke. Notably, the fluctuations argatroban brings to the coagulation test results might not be interpreted as increased bleeding risk. This case also suggested that the reported timing (day 6 to day 14 after hemorrhage) of anticoagulant resumption in primary intracerebral hemorrhage with mechanical valves might be late for some patients with HT.
Source: Frontiers in Pharmacology - December 16, 2020 Category: Drugs & Pharmacology Source Type: research

Thromboembolic and hemorrhagic outcomes in the direct oral anticoagulant trials across the spectrum of kidney function.
Abstract Chronic kidney disease (CKD) is a common comorbidity among patients taking direct-acting oral anticoagulants (DOACs). Herein, we evaluate the influence of kidney function on Stroke/SEE, hemorrhage and composite endpoints (Stroke/SEE/hemorrhage/death and Stroke/SEE/death) among patients on DOACs and warfarin. Baseline kidney function was categorized as GFR≥60 (reference), 45-59 and <45ml/min/1.73m2 for participants in the RE-LY (n=18,049), ARISTOTLE (n=18,187), and ENGAGE AF (n=20,798) trials. Incidence of events was compared across GFR categories. Hazard ratios for events was estimated using Cox regr...
Source: Clinical Pharmacology and Therapeutics - December 5, 2020 Category: Drugs & Pharmacology Authors: Limdi NA, Beasley TM, Sun J, Stockbridge N, Pacanowski M, Florian J Tags: Clin Pharmacol Ther Source Type: research

Left atrial or left atrial appendage thrombus as a cardiac source of embolus: that is the question or Faust bargain for left atrial appendage closure? —Authors’ reply
We thank Yakutet al. for their comments on our Point of view ‘Where are clots in atrial fibrillation? Did we have the wrong assumptions over the last decades?’. In the manuscript, we addressed how in the old literature the frequency of left atrial cavity thrombi is probably largely overestimated.1 In fact, based on an accurate review, and on our experience, the real frequency of atrial thrombi located outside the left appendage (LAA) is extremely low, and it might be an important rationale for LAA occlusion interventions. The aim of this last sentence was to give evidence to procedures focusing on LAA, not promoting LA...
Source: Europace - November 30, 2020 Category: Cardiology Source Type: research

Inactivated Four-Factor Prothrombin Complex Concentrate Dosing Practices for Reversal of Warfarin-Related Intracranial Hemorrhage
ConclusionsMost patients received single doses of I4F-PCC, with adjunctive reversal agents and rounding doses to vial size. The time difference from baseline INR to factor product administration is a potential opportunity for process improvement in the management of warfarin-related ICH.
Source: Neurocritical Care - November 20, 2020 Category: Neurology Source Type: research

Direct Oral Anticoagulants Versus Warfarin in the Treatment of Left Ventricular Thrombus.
CONCLUSION AND RELEVANCE: Our data suggest that DOACs may be reasonable alternatives for treatment of LV thrombus. When added to the totality of available studies, this study demonstrates that the effectiveness of DOACs in LV thrombus remains uncertain. Randomized clinical trials are needed. PMID: 33191781 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - November 15, 2020 Category: Drugs & Pharmacology Authors: Willeford A, Zhu W, Stevens C, Thomas IC Tags: Ann Pharmacother Source Type: research

Rivaroxaban Versus Warfarin in Patients with Mechanical Heart Valves: Open-Label, Proof-of-Concept trial —The RIWA study
ConclusionsIn this pilot study, rivaroxaban 15  mg twice daily had thromboembolic and bleeding events similar to warfarin in patients with mechanical heart valves. These data confirm the authors’ proof-of-concept and suggest that a larger trial with a similar design is not unreasonable.ClinicalTrial.gov identifierNCT03566303.
Source: American Journal of Cardiovascular Drugs - November 5, 2020 Category: Cardiology Source Type: research

Comparison of effects of triple antithrombotic therapy and dual antiplatelet therapy on long-term outcomes of acute myocardial infarction
This study aimed to compare the long-term outcome of triple antithrombotic therapy (TAT) with that of dual antiplatelet therapy (DAPT) after AMI. This was a nationwide, propensity score-matched, case –control study of 186,112 first AMI patients, of whom 2,825 received TAT comprising aspirin, clopidogrel, and warfarin. Propensity score matching in a ratio of 1:4 by age, sex, comorbidities, and treatment was adopted, Finally, 2,813 AMI patients and 11,252 matched controls that were administered TAT and DAPT (aspirin and clopidogrel), respectively, were included in our analysis. The 12-year overall survival rate did not dif...
Source: Heart and Vessels - October 8, 2020 Category: Cardiology Source Type: research

Long-term efficacy and safety of anticoagulation after atrial fibrillation ablation: data from the JACRE registry.
CONCLUSIONS: Long-term incidence of thromboembolism was extremely low in patients with AF treated with CA, while that of major bleeding was not especially low. Clinical Trials Registry: UMIN000032829 / UMIN000032830. PMID: 33011056 [PubMed - as supplied by publisher]
Source: Journal of Cardiology - September 29, 2020 Category: Cardiology Authors: Inoue K, Hirao K, Kumagai K, Kimura M, Miyauchi Y, Tsushima E, Ohishi M, Kimura K, Yasaka M, Yamaji H, Okawa K, Fujimoto M, Morishima I, Mine T, Shimizu W, Ohe M, Okumura K, JACRE Investigators Tags: J Cardiol Source Type: research

Risk of Stroke and Bleeding in Atrial Fibrillation Treated with Apixaban Compared with Warfarin
ConclusionIn NVAF patients of all ages initiating either apixaban or warfarin for stroke prevention in the Sentinel System, apixaban was associated with a decreased risk of GI bleeding, ICH, and ischemic stroke compared with warfarin. Among patients less than 65  years of age, apixaban use was associated with a decreased risk of GI bleeding and ischemic stroke.
Source: Journal of General Internal Medicine - September 27, 2020 Category: Internal Medicine Source Type: research

Clinical Trial Based Rationale for the Successful Use of DOAC in the Treatment of Cerebral Venous Sinus Thrombosis (CVST): A Case Report
In cerebral venous sinus thrombosis (CVST), venous sinus occlusion increases venous pressure and disrupts venous return, resulting in progression to venous infarction and venous hemorrhage, with poor neurologic outcome. Therefore, early recanalization of the major venous sinus is critical.Anticoagulant therapy with continuous intravenous infusion of heparin and subsequent oral anticoagulant administration is the recommended first line of treatment for CVST. Some large clinical trials for venous thromboembolism (VTE) have shown that direct oral anticoagulant (DOAC) is non-inferior to the standard therapy with heparin or war...
Source: Journal of Stroke and Cerebrovascular Diseases - September 3, 2020 Category: Neurology Authors: Toshiaki Bando, Yasushi Ueno, Daisuke Shimo, Takahiro Kuroyama, Kazuyuki Mikami, Shinya Hori, Osamu Hirai Tags: Case Report Source Type: research

Efficacy and Safety of Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Liver Disease: a Meta-Analysis and Systematic Review
ConclusionsOur findings suggest that DOACs significantly reduce the risk of ischemic stroke, major bleeding, and ICH, with no significant effect on the risk of gastrointestinal bleeding in AF patients with liver disease compared with warfarin.
Source: Cardiovascular Drugs and Therapy - September 2, 2020 Category: Cardiology Source Type: research

Seasonal Variations in the Incidence of Ischemic Stroke, Extracranial and Intracranial Hemorrhage in Atrial Fibrillation Patients.
CONCLUSIONS: Significant seasonal variations were observed for IS, ECH, and ICH events in AF patients, and were consistently the highest in winter. A small peak of ECH was observed in summer, which seemed, in part, to be related to increased DOAC use. PMID: 32863288 [PubMed - as supplied by publisher]
Source: Circulation Journal - August 27, 2020 Category: Cardiology Authors: Oida M, Suzuki S, Arita T, Yagi N, Otsuka T, Kishi M, Semba H, Kano H, Matsuno S, Kato Y, Uejima T, Oikawa Y, Hoshino S, Matsuhama M, Inoue T, Yajima J, Yamashita T Tags: Circ J Source Type: research

Moving towards ideal and appropriate models of anticoagulation management service
This article seeks to discuss how the establishment of appropriate models of anticoagulation could contain the draw backs of the old anticoagulants and improve on the compliance, availability, affordability, and accessibility of newer anticoagulants. Successful anticoagulation has always been defined by a scientific balancing of the risk of thrombosis and the complication of hemorrhage. To be able to maintain such optimal anticoagulation requires rational drug prescription (physician factor), institutelization of monitoring of therapy (anticoagulation clinic factor) as well as active participation of patients receiving the...
Source: Annals of African Medicine - August 18, 2020 Category: African Health Authors: Anakwue Raphael Source Type: research